Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Baxter
Teva
Harvard Business School
Express Scripts
Cipla
US Army
Fish and Richardson
Mallinckrodt

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,579,981

« Back to Dashboard

Which drugs does patent 6,579,981 protect, and when does it expire?

Patent 6,579,981 protects DENAVIR and is included in one NDA.

This patent has seventy-one patent family members in twenty-seven countries.
Summary for Patent: 6,579,981
Title: Antiviral guanine derivatives
Abstract:A compound of formula (I) ##STR1## or a salt or acyl derivative thereof, in which X represents chlorine, C.sub.1-6 alkoxy, phenoxy, phenyl C.sub.1-6 alkoxy, NH.sub.2, --OH or --SH, is useful in treating viral infections.
Inventor(s): Jarvest; Richard Lewis (Surbiton, GB), Harnden; Michael Raymond (Horsham, GB)
Assignee: Novartis International Pharmaceutical Ltd. (Hamilton, BM)
Application Number:08/311,291
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,579,981
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Formulation;

Drugs Protected by US Patent 6,579,981

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mylan Pharms Inc DENAVIR penciclovir CREAM;TOPICAL 020629-001 Sep 24, 1996 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,579,981

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8325271Sep 21, 1908
United Kingdom8322199Aug 18, 1983
United Kingdom8408322Mar 30, 1984

Non-Orange Book US Patents Family Members for Patent 6,579,981

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,684,153 Process for the preparation of purine derivatives ➤ Sign Up
6,187,922 Process for the preparation of purine derivatives ➤ Sign Up
6,388,074 Process for the preparation of purine derivatives ➤ Sign Up
5,075,445 Guanine derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Fuji
Teva
Daiichi Sankyo
QuintilesIMS
Deloitte
Colorcon
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.